Figure 8.
Combined treatment with ICIs enhances antitumor immunity.
(a) Schema for tumor implantation. MO4 tumor-bearing C57BL/6 mice were left untreated or treated with the OVA257-264 peptide-loaded GM-pMCs on days 4 and 11, and ICIs on days 5, 8, 12, and 15. (b–j) Tumors were harvested on day 16, and the intratumoral immune cells were assessed using flow cytometry. (b, e, h) Representative flow cytometry profiles. Graph data represents frequency (c, f, i) and absolute number (per gram of tumor tissue) (d, g, j) of indicated cells. Mean ± SD are shown (n = 5 mice). *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001.